Project Grant R01HL173242
Award Date
1/10/25
Completion Date
12/31/28
Dollars Obligated
$693K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $361,083 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Children's Hospital Medical Center in Cincinnati, OH. The grant supports research on how acetylation regulates the subcellular localization of the transcription factor YAP and its role in cardiac regeneration. The 5-year project aims to investigate how metabolic stresses affect YAP acetylation through the NAD+/SIRT1/2 axis, and whether...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $560,000 to Baylor College of Medicine to perform preclinical testing and development of a novel "triple gene therapy" approach for treating ischemic heart failure. The proposed therapy aims to regenerate damaged heart muscle by inducing cardiomyocyte proliferation, direct cardiac reprogramming of fibroblasts, and enhancing...
This Project Grant award of $746,800 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Baylor College of Medicine to define the major signaling mechanism controlling spontaneous cardiomyocyte (CM) proliferation in the neonatal stage. The research aims to understand how the transmembrane scavenger receptor CD36 modulates retinoic acid (RA) signaling to regulate CM cell cycle progression, with the goal of identifying...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $156,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Texas Southwestern Medical Center (UT Southwestern). The 5-year grant will support research to define the role of the PHF7 protein in driving cardiac reprogramming and improving heart function following a myocardial infarction. Specifically, the project aims to: 1) Characterize...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $655,636 in funding to the Texas Heart Institute (THI) to investigate the role of cardiac fibroblasts in the development of heart failure in patients with single ventricle congenital heart disease. The objectives are to gain insights into the intrinsic molecular mechanisms that promote cellular senescence, metabolic remodeling, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding research at the Texas Heart Institute (THI) to elucidate the role of senescent cardiac tissue-resident macrophages in heart failure progression. The $651,967 award, effective from August 1, 2025 to May 31, 2030, will support mechanistic studies to understand how macrophage senescence promotes cardiomyocyte dysfunction,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to advance understanding of the role of endothelial epsins in regulating myocardial ischemia and heart regeneration. The $833,681 award to The Children's Hospital Corporation (Boston Children's Hospital) will fund research to decipher the molecular mechanisms by which targeting cardiac endothelial epsins can enhance...
This federal Project Grant award of $2,249,307, provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), aims to study the premature maturation arrest of pluripotent-derived cardiomyocytes (PSC-CMs) and develop strategies to overcome this issue. The project will leverage a high-resolution single cell transcriptome map of endogenous cardiomyocyte maturation to identify a critical gene regulatory network underlying the maturation failure in PSC-CMs....
The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...